AVITA Medical reports developments in therapeutic acute wound care, led by the RECELL platform for Spray-On Skin used in burn and trauma wounds. Company news commonly covers FDA-cleared wound-care indications, RECELL GO automation, international regulatory clearances, and the U.S. commercial portfolio that includes Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix.
Updates also include clinical data presentations, BARDA emergency-preparedness agreements, quarterly financial results, investor-conference participation, and board or executive governance changes. The recurring news themes connect AVITA Medical's product platform with acute burn care, trauma wound treatment, commercialization, reimbursement, and capital resources.
AVITA Medical (NASDAQ: RCEL) reported third-quarter 2026 revenue of approximately $26.1 million, up 53% from the prior-year period. Revenue rose 20% sequentially, and gross margin increased to 84.0% from 81.3% a year earlier. Net loss narrowed to $6.2 million, or $0.20 per share, from $13.2 million, or $0.46 per share.
The company raised full-year revenue guidance to $92 million–$94 million from $86 million–$89 million and reaffirmed expected fourth-quarter cash flow breakeven. Quarterly net cash use improved to approximately $0.6 million, leaving approximately $10.5 million in cash and securities at September 30. After quarter-end, AVITA drew another $10 million under its credit facility, bringing total borrowings to $60 million. The going-concern qualification was removed. CMS finalized RECELL physician payment values and simplified billing codes, effective January 1, 2027.
AVITA Medical (NASDAQ: RCEL) announced finalized national Medicare physician valuations for RECELL procedures, effective January 1, 2027, replacing regionally set valuations. CMS will also replace eight billing codes with four codes for skin cell suspension autograft procedures, which use a patient's skin cells. The bundled structure covers skin harvesting, cell preparation and application, removing separate coding for manual and automated preparation.
AVITA expects the changes to simplify reporting and make physician payment more predictable. CMS also finalized facility payment assignments and rates for the new codes in hospital outpatient and ambulatory surgery settings. Physician payments remain separate from facility payments, and Medicare coverage policies continue to apply.
AVITA Medical (RCEL) will report third-quarter 2026 financial results after U.S. financial markets close on November 5, 2026.
A conference call and webcast will follow that day at 1:30 p.m. Pacific Time, corresponding to November 6 at 8:30 a.m. Australian Eastern Daylight Time, to discuss results and recent business highlights. A replay will be available on the Events page of the company’s investor relations website.
AVITA Medical (RCEL) will participate in two investor events in New York in September 2026: Lake Street Capital Markets’ 10th Annual Best Ideas Growth Conference on September 10 and Morgan Stanley’s 24th Annual Global Healthcare Conference on September 16.
President and CEO Cary Vance and CFO David O’Toole will host investor meetings at both conferences and join a fireside chat at the Morgan Stanley event at 1:05 p.m. ET. A live audio webcast and 90-day replay of this fireside chat will be accessible in the Investor Relations section of AVITA Medical’s website.
AVITA Medical (NASDAQ: RCEL) reported positive results from its multicenter, randomized controlled PermeaDerm-I study, showing PermeaDerm, a biosynthetic wound matrix, achieved the primary endpoint of a 70% economic advantage over cadaveric allograft based on mean product cost per percent total body surface area (%TBSA) treated (p<0.001).
According to the company, mean treatment cost was $148.70 per 1% TBSA with PermeaDerm versus $497.10 with allograft, a savings of about $348 per %TBSA. PermeaDerm reduced preparation time by 95.7% by eliminating tissue tracking, thawing, and meshing, while maintaining comparable operating room application time.
Clinical outcomes were comparable: about 94% of PermeaDerm patients achieved at least 95% graft take at one week, and all patients in both arms reached ≥95% wound healing by eight weeks, with no adverse events attributed to PermeaDerm. The study enrolled 40 patients across 11 U.S. burn centers. AVITA Medical will host a Key Opinion Leader webinar to review the data on August 18, 2026, at 4:30 p.m. ET.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) will host an investor webinar briefing on August 12, 2026, at 4:00 p.m. Pacific Time (August 13, 2026, 9:00 a.m. AEST). President and CEO Cary Vance and CFO David O’Toole will present financial and business highlights from the recent Q2 2026 earnings webcast, followed by a Q&A session. Investors can register via Zoom, and a replay will be available on the AVITA Medical investor relations website.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, held August 11–13, 2026. President and CEO Cary Vance is scheduled to speak on Wednesday, August 12, 2026, at 8:00 a.m. Eastern Time.
A live webcast and replay of the presentation will be accessible via the Investor Relations Events & Presentations section of AVITA Medical’s website. Investors attending the conference can request one-on-one meetings with AVITA Medical through their Canaccord Genuity sales representative.
AVITA Medical (NASDAQ: RCEL) reported Q2 2026 revenue of $21.7 million, up 18% year over year and 13% sequentially, with a record gross margin of 81.9% and operating expenses reduced 6% to $24.6 million. Net loss improved to $7.7 million ($0.25 per share).
Growth was led by RECELL (Q2 revenue $18.5 million), supported by Cohealyx ($1.7 million), PermeaDerm ($0.6 million), and international sales ($0.9 million). According to AVITA Medical, net cash use fell to approximately $3.2 million, with quarter-end liquidity of $11.1 million.
The company raised its 2026 revenue guidance to $86–$89 million (20–24% growth over 2025) and now expects cash flow breakeven in Q4 2026. AVITA Medical also highlighted proposed 2027 CMS Medicare payment updates for procedures using RECELL that would introduce national physician payment and higher facility rates if finalized.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) announced it will release its second quarter 2026 financial results after the close of U.S. financial markets on Thursday, August 6, 2026.
The company will host a conference call and webcast at 1:30 p.m. Pacific Time the same day (6:30 a.m. AEST on Friday, August 7, 2026) to review results and recent business highlights. Investors can access the webcast and register for dial-in details via provided online links, and a replay will be available on the investor relations Events page.
AVITA Medical (NASDAQ: RCEL) reported first U.K. clinical experience with RECELL GO in 17 burn and reconstructive patients at the 2026 British Burn Association meeting.
According to AVITA Medical, all patients had successful treatment and discharge, with noted workflow benefits, and RECELL GO is CE-marked in Europe/U.K. and authorized in Australia and New Zealand. A separate review of 99 studies in 8,000+ patients found RECELL to be a safe, effective, evidence-based wound management approach.